Trial reportMolecular psychiatry2007
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.
Trial report in Molecular psychiatry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00752960 (DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics
Who cites it
24 citing papers in PubMed, 62 citations in OpenAlex.
- Association of a Single-Nucleotide Variant rs11100494 of thePharmaceutics · 2022Article
- Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone.Frontiers in pharmacology · 2021Review
- Risk Associated with theAntioxidants (Basel, Switzerland) · 2020Article
- Physicians' Perspective on Diabetes Mellitus Management within the Context of Personalized Medicine Era in Tabuk Governorate, Saudi Arabia.Open access Macedonian journal of medical sciences · 2019Article
- Associations between theMolecular neuropsychiatry · 2018Article
- Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.The pharmacogenomics journal · 2013Article
- 'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine.Pharmacogenomics · 2012Article
- Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients.Progress in neuro-psychopharmacology & biological psychiatry · 2012Article
- Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.Molecular psychiatry · 2012Review
- Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients.Biomarkers in medicine · 2011Article
- Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications.Pharmacogenomics · 2011Review
- Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?Pharmacogenomics · 2010Article
- Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole.International journal of obesity (2005) · 2010Article
- Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents.Psychiatric genetics · 2009Article
- Acetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels.Schizophrenia research · 2009Article
- Physiogenomic analysis of the Puerto Rican population.Pharmacogenomics · 2009Article
- Refractory restless legs syndrome likely caused by olanzapine.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2009Article
- Physiogenomic analysis of localized FMRI brain activity in schizophrenia.Annals of biomedical engineering · 2008Article
- Personalized medicine for diabetes.Journal of diabetes science and technology · 2008Article
- Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.Schizophrenia research · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Atypical antipsychotics induce pre-diabetic symptoms in some but not all patients, characterized most notably by elevated weight. The side effect profiles of the various drugs in the class differ, however, raising the possibility of drug-specific mechanisms for similar side effects. We used physiogenomic analysis, an approach previously employed to study the genetics of drug and diet response, to discover and compare genetic associations with weight profiles observed in patients treated with olanzapine and risperidone as an approach to unraveling contrasting mechanistic features of both drugs. A total of 29 single nucleotide polymorphisms (SNPs) were selected from 13 candidate genes relevant to two potential pharmacological axes of psychotropic-related weight profiles, appetite peptides and peripheral lipid homeostasis. We applied physiogenomic analysis to a cross-section of 67 and 101 patients being treated with olanzapine and risperidone, respectively, and assessed genetic associations with the weight profiles. Weight profiles in patients treated with olanzapine were significantly associated with SNPs in the genes for apolipoprotein E, apolipoprotein A4 and scavenger receptor class B, member 1. Weight profiles in patients treated with risperidone were significantly associated with SNPs in the genes for leptin receptor, neuropeptide Y receptor Y5 and paraoxonase 1. These results are consistent with contrasting mechanisms for the weight profile of patients treated with these drugs. Genes associated with olanzapine weight profiles may be related to peripheral lipid homeostatic axes, whereas those associated with risperidone's may be related to brain appetite peptide regulation. Future physiogenomic studies will include neurotransmitter receptor SNPs and validation in independent samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.